E-resources
-
Sibbing, Dirk; Aradi, Daniel; Alexopoulos, Dimitrios; ten Berg, Jurrien; Bhatt, Deepak L.; Bonello, Laurent; Collet, Jean-Philippe; Cuisset, Thomas; Franchi, Francesco; Gross, Lisa; Gurbel, Paul; Jeong, Young-Hoon; Mehran, Roxana; Moliterno, David J.; Neumann, Franz-Josef; Pereira, Naveen L.; Price, Matthew J.; Sabatine, Marc S.; So, Derek Y.F.; Stone, Gregg W.; Storey, Robert F.; Tantry, Udaya; Trenk, Dietmar; Valgimigli, Marco; Waksman, Ron; Angiolillo, Dominick J.
JACC. Cardiovascular interventions, 08/2019, Volume: 12, Issue: 16Journal Article
Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or de-escalation of P2Y12-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early- vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention–treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT de-escalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention. Display omitted •Different P2Y12 inhibitors have enabled physicians to contemplate individualized treatment regimens.•In selective scenarios, PFT and genotyping may be used as optional tools for guiding treatment.•Further studies on DAPT de-escalation and escalation are needed to refine existing treatment options.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.